ArticleInternational journal of molecular sciences2024

Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.

Martina Nasello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.